Skip to main content
Figure 3 | Molecular Cancer

Figure 3

From: YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma

Figure 3

Combination of sorafenib and YC-1 suppressed the activity of STAT3 and expression of its associated protein. HepG2, BEL-7402 and HCCLM3 cells were incubated with sorafenib (5 μmol/L) in combination with YC-1 (10 μmol/L or 20 μmol/L) or either drug alone for 24 h. A. Cell extracts were subjected to western blot analysis and expression of p-STAT3 (Y705), STAT3, cyclin D1 and survivin was assessed. Actin served as loading control. B. SHP-1 activity was measured in HepG2 and BEL-7402 cells.

Back to article page

Molecular Cancer

ISSN: 1476-4598